Ziolkowska-Banasik, D.; Pastuszczak, M.; Zawadzinska-Halat, K.; Hadas, E.; Bozek, A.
Serum IL-18/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis. Int. J. Mol. Sci. 2025, 26, 6432.
https://doi.org/10.3390/ijms26136432
AMA Style
Ziolkowska-Banasik D, Pastuszczak M, Zawadzinska-Halat K, Hadas E, Bozek A.
Serum IL-18/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis. International Journal of Molecular Sciences. 2025; 26(13):6432.
https://doi.org/10.3390/ijms26136432
Chicago/Turabian Style
Ziolkowska-Banasik, Dominika, Maciej Pastuszczak, Kamila Zawadzinska-Halat, Ewa Hadas, and Andrzej Bozek.
2025. "Serum IL-18/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis" International Journal of Molecular Sciences 26, no. 13: 6432.
https://doi.org/10.3390/ijms26136432
APA Style
Ziolkowska-Banasik, D., Pastuszczak, M., Zawadzinska-Halat, K., Hadas, E., & Bozek, A.
(2025). Serum IL-18/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis. International Journal of Molecular Sciences, 26(13), 6432.
https://doi.org/10.3390/ijms26136432